Atossa Therapeutics Files 8-K Report
Ticker: ATOS · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1488039
Sentiment: neutral
Topics: 8-K, SEC filing, financials
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On September 8, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Atossa Therapeutics is providing updates to the SEC, which could include important operational or financial information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, which typically contains routine disclosures and does not inherently signal high risk without further context.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 26-4753208 (identifier) — IRS Employer Identification No.
- 10202 5th Avenue NE, Suite 200 (address) — Principal Executive Offices
- Seattle, Washington (location) — City and State of Principal Executive Offices
- 98125 (zip_code) — Zip Code of Principal Executive Offices
- ( 206 ) 588-0256 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Atossa Therapeutics, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported; it only lists the item category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The excerpt indicates that "Financial Statements and Exhibits" are part of the filing, but it does not specify which statements or exhibits are included.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 8, 2025, which is also the date of the report.
What is Atossa Therapeutics, Inc.'s principal executive office address?
Atossa Therapeutics, Inc.'s principal executive office is located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
What is the Commission File Number for Atossa Therapeutics, Inc.?
The Commission File Number for Atossa Therapeutics, Inc. is 001-35610.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-09-08 08:36:48
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20250908.htm (8-K) — 49KB
- atos-ex99_1.htm (EX-99.1) — 54KB
- img248274862_0.jpg (GRAPHIC) — 668KB
- 0000950170-25-113371.txt ( ) — 1142KB
- atos-20250908.xsd (EX-101.SCH) — 28KB
- atos-20250908_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On September 8, 2025, Atossa Therapeutics, Inc. (the "Company") announced a new regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated September 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: September 8, 2025 By: /s/ Steven C. Quay Steven C. Quay, M.D., Ph.D. Chairman, President and Chief Executive Officer